Melatonin reduces COVID-19 risk: real-time meta analysis of 19 studies

@CovidAnalysis, July 2025, Version 26
https://c19early.org/jmeta.html

Abstract

Significantly lower risk is seen for mortality, ventilation, and recovery. 10 studies from 10 independent teams in 6 countries show significant benefit.

Meta analysis using the most serious outcome reported shows 43% [31-54%] lower risk. Results are similar for higher quality studies and slightly worse for Randomized Controlled Trials and peer-reviewed studies. Early treatment is more effective than late treatment.

3 RCTs with 268 patients have not reported results (up to 4 years late).

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Dietary sources may be preferred. The quality of non-prescription supplements varies widely [1-3]. All data and sources to reproduce this analysis are in the appendix.

7 other meta analyses show significant improvements with melatonin for mortality [4-7], mechanical ventilation [8], hospitalization [6,8], clinical improvement [8], and recovery [9,10].





MELATONIN FOR COVID-19 — HIGHLIGHTS

Melatonin reduces risk with very high confidence for mortality, ventilation, recovery, and in pooled analysis, low confidence for cases, and very low confidence for ICU admission and hospitalization.

Early treatment is more effective than late treatment.

11th treatment shown effective in December 2020, now with $p = 0.000000047$ from 19 studies.

Real-time updates and corrections with a consistent protocol for 172 treatments. Outcome specific analysis and combined evidence from all studies including treatment delay, a primary confounding factor.





***Figure 1.* A. Random effects meta-analysis.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix. **B. Timeline of results in melatonin studies.** The marked dates indicate the time when efficacy was known with a statistically significant improvement of ≥10% from ≥3 studies for pooled outcomes, one or more specific outcome, and pooled outcomes in RCTs. Efficacy based on RCTs only was delayed by 22.6 months, compared to using all studies. Efficacy based on specific outcomes was delayed by 8.0 months, compared to using pooled outcomes.

Introduction

Immediate treatment recommended

SARS-CoV-2 infection primarily begins in the upper respiratory tract and may progress to the lower respiratory tract, other tissues, and the nervous and cardiovascular systems, which may lead to cytokine storm, pneumonia, ARDS, neurological injury[12-24] and cognitive deficits[15,20], cardiovascular complications[25-29], organ failure, and death. Even mild untreated infections may result in persistent cognitive deficits[30]—the spike protein binds to fibrin leading to fibrinolysis-resistant blood clots, thromboinflammation, and neuropathology. Minimizing replication as early as possible is recommended.



Figure 2. **SARS-CoV-2 spike protein fibrin binding leads to thromboinflammation and neuropathology, from[11].**

Many treatments are expected to modulate infection

SARS-CoV-2 infection and replication involves the complex interplay of 100+ host and viral proteins and other factors[A,31-38], providing many therapeutic targets for which many existing compounds have known activity. Scientists have predicted that over 9,000 compounds may reduce COVID-19 risk[39], either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications.

Supporting research

Melatonin may restore altered redox homeostasis in COVID-19[40], modulates type III interferon responses and reduces inflammatory cytokine production in TLR3 receptor agonist stimulated viral inflammation while preserving tissue integrity[41], and negatively regulates genes critical for viral entry in lung tissue, including reduced expression of FURIN and components of the CD147 complex, while potentially disrupting TMPRSS2/ACE2-mediated entry mechanisms[42]. Melatonin reduces oxidative stress, inhibits NET formation, and protects tissues through anti-inflammatory and antioxidant actions[43].

Analysis

We analyze all significant controlled studies of melatonin for COVID-19. Search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), all individual study data, PRISMA answers, and statistical methods are detailed in Appendix 1. We present random effects meta-analysis results for all studies, studies within each treatment stage, individual outcomes, peer-reviewed studies, Randomized Controlled Trials (RCTs), and higher quality studies.

Treatment timing

Figure 3 shows stages of possible treatment for COVID-19. Prophylaxis refers to regularly taking medication before becoming sick, in order to prevent or minimize infection. Early Treatment refers to treatment immediately or soon after symptoms appear, while Late Treatment refers to more delayed treatment.



Figure 3. **Treatment stages.**

Mechanisms of Action

Table 1 shows potential mechanisms of action for the treatment of COVID-19 using melatonin.

CD147	SARS-CoV-2 may enter host cells via the cluster of differentiation 147 (CD147) transmembrane protein. Melatonin inhibits the CD147 signaling pathway[44-46].
Heme oxygenase	COVID-19 risk may be related to low intracellular heme oxygenase (HO-1). Melatonin increases HO-1 and HO-1 has cytoprotective and anti-inflammatory properties[47-51].
Inhibiting brain infection	Melatonin has been shown to inhibit SARS-CoV-2 brain infection in a K18-hACE2 mouse model via allosteric binding to ACE2[52].
Limiting type I and III interferons	In a K18-hACE2 mouse model, melatonin improved survival which may be associated with limiting lung production of type I and type III interferons[53].
Viral phase separation	Melatonin may be beneficial via regulation of viral phase separation, such as modulating the liquid-liquid phase separation of the SARS-CoV-2 nucleocapsid protein to inhibit formation of viral replication factories[54].
Mucormycosis	Melatonin deficiency may increase the risk of mucormycosis by providing favorable conditions for growth[55].
Glutathione	Melatonin increases glutathione levels, and glutathione deficiency may be associated with COVID-19 severity[56,57].
Cytokine levels	Melatonin may lower pro-inflammatory cytokine levels[58].
Immune regulation	Melatonin has immune regulatory properties, enhancing the proliferation and maturation of natural killing cells, T and B lymphocytes, granulocytes, and monocytes[58,59].
Sleep improvement	Melatonin improves the quality of sleep which may be beneficial for COVID-19[58,60].
Anti-inflammatory	Melatonin shows anti-inflammatory effects[58].
Anti-oxidation	Melatonin shows anti-oxidative effects which may be beneficial for COVID-19[58,61-64].

Table 1. **Melatonin mechanisms of action.**

Preclinical Research

Melatonin may restore altered redox homeostasis in COVID-19[40], modulates type III interferon responses and reduces inflammatory cytokine production in TLR3 receptor agonist stimulated viral inflammation while preserving tissue integrity[41], and negatively regulates genes critical for viral entry in lung tissue, including reduced expression of FURIN and components of the CD147 complex, while potentially disrupting TMPRSS2/ACE2-mediated entry mechanisms[42].

3 *In Silico* studies support the efficacy of melatonin[42,65,66].

An *In Vitro* study supports the efficacy of melatonin[41].

3 *In Vivo* animal studies support the efficacy of melatonin[42,52,53].

Preclinical research is an important part of the development of treatments, however results may be very different in clinical trials. Preclinical results are not used in this paper.

Results

Table 2 summarizes the results for all stages combined, for Randomized Controlled Trials, for peer-reviewed studies, after exclusions, and for specific outcomes. Table 3 shows results by treatment stage. Figure 4 plots individual results by treatment stage. Figure 5, 6, 7, 8, 9, 10, 11, 12, and 13 show forest plots for random effects meta-analysis of all studies with pooled effects, mortality results, ventilation, ICU admission, hospitalization, progression, recovery, cases, and peer reviewed studies.

	Relative Risk	Studies	Patients
All studies	0.57 [0.46-0.69] ****	19	10K
After exclusions	0.54 [0.43-0.67] ****	17	10K
Peer-reviewed	0.67 [0.58-0.77] ****	18	10K
RCTs	0.74 [0.57-0.96] *	9	1,022
Mortality	0.52 [0.38-0.72] ****	10	2,656
Ventilation	0.71 [0.60-0.86] ***	3	324
ICU admission	0.94 [0.85-1.04]	5	271
Hospitalization	0.81 [0.60-1.09]	3	366
Recovery	0.70 [0.57-0.85] ***	6	474
Cases	0.62 [0.36-1.06]	3	10K
RCT mortality	0.75 [0.52-1.07]	4	547

Table 2. **Random effects meta-analysis for all stages combined, for Randomized Controlled Trials, for peer-reviewed studies, after exclusions, and for specific outcomes.** Results show the relative risk with treatment and the 95% confidence interval. * $p<0.05$ *** $p<0.001$ **** $p<0.0001$.

	Early treatment	Late treatment	Prophylaxis
All studies	0.22 [0.06-0.75] *	0.55 [0.43-0.72] ****	0.62 [0.36-1.06]
After exclusions	0.22 [0.06-0.75] *	0.52 [0.38-0.70] ****	0.62 [0.36-1.06]
Peer-reviewed	0.22 [0.06-0.75] *	0.68 [0.57-0.81] ****	0.62 [0.36-1.06]
RCTs	0.27 [0.07-1.05]	0.77 [0.59-1.00] *	0.93 [0.06-14.68]
Mortality		0.52 [0.38-0.72] ****	
Ventilation		0.71 [0.60-0.86] ***	
ICU admission		0.94 [0.85-1.04]	
Hospitalization	0.09 [0.01-1.57]	0.84 [0.67-1.06]	
Recovery	0.27 [0.07-1.05]	0.72 [0.59-0.86] ***	
Cases			0.62 [0.36-1.06]
RCT mortality		0.75 [0.52-1.07]	

Table 3. **Random effects meta-analysis results by treatment stage.** Results show the relative risk with treatment and the 95% confidence interval. * $p<0.05$ *** $p<0.001$ **** $p<0.0001$.



Figure 4. **Scatter plot showing the most serious outcome in all studies, and for studies within each stage.** Diamonds shows the results of random effects meta-analysis.



Figure 5. **Random effects meta-analysis for all studies.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.



Figure 6. Random effects meta-analysis for mortality results.



Figure 7. Random effects meta-analysis for ventilation.



Figure 8. Random effects meta-analysis for ICU admission.



Figure 9. Random effects meta-analysis for hospitalization.



Figure 10. Random effects meta-analysis for progression.



Figure 11. Random effects meta-analysis for recovery.



Figure 12. Random effects meta-analysis for cases.



Figure 13. **Random effects meta-analysis for peer reviewed studies.** Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details. Analysis validating pooled outcomes for COVID-19 can be found below. *Zeraatkar et al.* analyze 356 COVID-19 trials, finding no significant evidence that preprint results are inconsistent with peer-reviewed studies. They also show extremely long peer-review delays, with a median of 6 months to journal publication. A six month delay was equivalent to around 1.5 million deaths during the first two years of the pandemic. Authors recommend using preprint evidence, with appropriate checks for potential falsified data, which provides higher certainty much earlier. *Davidson et al.* also showed no important difference between meta analysis results of preprints and peer-reviewed publications for COVID-19, based on 37 meta analyses including 114 trials.

Dose Response

Melatonin trials for COVID-19 use a very wide range of dosage, from 2mg/day to 500mg/day[69]. Figure 14 shows a mixed-effects meta-regression for efficacy as a function of dose from studies to date, excluding very late stage ICU studies. Results suggest that the dosage used in many trials to date is lower than optimal.



Figure 14. **Mixed-effects meta-regression showing efficacy as a function of dose.**
Very late stage ICU studies are excluded.

Randomized Controlled Trials (RCTs)

Figure 15 shows a comparison of results for RCTs and observational studies. Figure 16 and 17 show forest plots for random effects meta-analysis of all Randomized Controlled Trials and RCT mortality results. RCT results are included in Table 2 and Table 3.



Figure 15. **Results for RCTs and observational studies.**

RCTs have many potential biases

RCTs help to make study groups more similar and can provide a higher level of evidence, however they are subject to many biases[70], and analysis of double-blind RCTs has identified extreme levels of bias[71]. For COVID-19, the overhead may delay treatment, dramatically compromising efficacy; they may encourage monotherapy for simplicity at the cost of efficacy which may rely on combined or synergistic effects; the participants that sign up may not reflect real world usage or the population that benefits most in terms of age, comorbidities, severity of illness, or other factors; standard of care may be compromised and unable to evolve quickly based on emerging research for new diseases;

errors may be made in randomization and medication delivery; and investigators may have hidden agendas or vested interests influencing design, operation, analysis, reporting, and the potential for fraud. All of these biases have been observed with COVID-19 RCTs. There is no guarantee that a specific RCT provides a higher level of evidence.

Conflicts of interest for COVID-19 RCTs

RCTs are expensive and many RCTs are funded by pharmaceutical companies or interests closely aligned with pharmaceutical companies. For COVID-19, this creates an incentive to show efficacy for patented commercial products, and an incentive to show a lack of efficacy for inexpensive treatments. The bias is expected to be significant, for example *Als-Nielsen et al.* analyzed 370 RCTs from Cochrane reviews, showing that trials funded by for-profit organizations were 5 times more likely to recommend the experimental drug compared with those funded by nonprofit organizations. For COVID-19, some major philanthropic organizations are largely funded by investments with extreme conflicts of interest for and against specific COVID-19 interventions.

RCTs for novel acute diseases requiring rapid treatment

High quality RCTs for novel acute diseases are more challenging, with increased ethical issues due to the urgency of treatment, increased risk due to enrollment delays, and more difficult design with a rapidly evolving evidence base. For COVID-19, the most common site of initial infection is the upper respiratory tract. Immediate treatment is likely to be most successful and may prevent or slow progression to other parts of the body. For a non-prophylaxis RCT, it makes sense to provide treatment in advance and instruct patients to use it immediately on symptoms, just as some governments have done by providing medication kits in advance. Unfortunately, no RCTs have been done in this way. Every treatment RCT to date involves delayed treatment. Among the 172 treatments we have analyzed, 67% of RCTs involve very late treatment 5+ days after onset. No non-prophylaxis COVID-19 RCTs match the potential real-world use of early treatments. They may more accurately represent results for treatments that require visiting a medical facility, e.g., those requiring intravenous administration.

RCT bias for widely available treatments

RCTs have a bias against finding an effect for interventions that are widely available — patients that believe they need the intervention are more likely to decline participation and take the intervention. RCTs for melatonin are more likely to enroll low-risk participants that do not need treatment to recover, making the results less applicable to clinical practice. This bias is likely to be greater for widely known treatments, and may be greater when the risk of a serious outcome is overstated. This bias does not apply to the typical pharmaceutical trial of a new drug that is otherwise unavailable.

Observational studies have been shown to be reliable

Evidence shows that observational studies can also provide reliable results. *Concato et al.* found that well-designed observational studies do not systematically overestimate the magnitude of the effects of treatment compared to RCTs. *Anglemyer et al.* analyzed reviews comparing RCTs to observational studies and found little evidence for significant differences in effect estimates. We performed a similar analysis across the 172 treatments we cover, showing no significant difference in the results of RCTs compared to observational studies, RR 0.98 [0.92-1.05][76]. Similar results are found for all low-cost treatments, RR 1.00 [0.91-1.09]. High-cost treatments show a non-significant trend towards RCTs showing greater efficacy, RR 0.92 [0.84-1.02]. Details can be found in the supplementary data. *Lee et al.* showed that only 14% of the guidelines of the Infectious Diseases Society of America were based on RCTs. Evaluation of studies relies on an understanding of the study and potential biases.



Figure 18. **For COVID-19, observational study results do not systematically differ from RCTs, RR 0.98 [0.92-1.05] across 172 treatments[73].**

Limitations in an RCT can outweigh the benefits, for example excessive dosages, excessive treatment delays, or remote survey bias may have a greater effect on results. Ethical issues may also prevent running RCTs for known effective treatments. For more on issues with RCTs see [78,79].

Using all studies identifies efficacy 8+ months faster (9+ months for low-cost treatments)

Currently, 55 of the treatments we analyze show statistically significant efficacy or harm, defined as ≥10% decreased risk or >0% increased risk from ≥3 studies. Of these, 58% have been confirmed in RCTs, with a mean delay of 7.7 months (64% with 8.9 months delay for low-cost treatments). The remaining treatments either have no RCTs, or the point estimate is consistent.

Summary

We need to evaluate each trial on its own merits. RCTs for a given medication and disease may be more reliable, however they may also be less reliable. For off-patent medications, very high conflict of interest trials may be more likely to be RCTs, and more likely to be large trials that dominate meta analyses.



Figure 16. **Random effects meta-analysis for all Randomized Controlled Trials.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.



Figure 17. Random effects meta-analysis for RCT mortality results.

Unreported RCTs

3 melatonin RCTs have not reported results [80-82]. The trials report a total of 268 patients, with 2 trials having actual enrollment of 168, and the other estimated. The results are delayed from 2 years to over 4 years.

Exclusions

To avoid bias in the selection of studies, we analyze all non-retracted studies. Here we show the results after excluding studies with major issues likely to alter results, non-standard studies, and studies where very minimal detail is currently available. Our bias evaluation is based on analysis of each study and identifying when there is a significant chance that limitations will substantially change the outcome of the study. We believe this can be more valuable than checklist-based approaches such as Cochrane GRADE, which can be easily influenced by potential bias, may ignore or underemphasize serious issues not captured in the checklists, and may overemphasize issues unlikely to alter outcomes in specific cases (for example certain specifics of randomization with a very large effect size and well-matched baseline characteristics).

The studies excluded are as below. Figure 19 shows a forest plot for random effects meta-analysis of all studies after exclusions.

Alizadeh, extremely late treatment, over 75% control mortality.

Sánchez-González, immortal time bias may significantly affect results.



Figure 19. **Random effects meta-analysis for all studies after exclusions.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.

Heterogeneity

Heterogeneity in COVID-19 studies arises from many factors including:

Treatment delay

The time between infection or the onset of symptoms and treatment may critically affect how well a treatment works. For example an antiviral may be very effective when used early but may not be effective in late stage disease, and may even be harmful. Oseltamivir, for example, is generally only considered effective for influenza when used within 0-36 or 0-48 hours[85,86]. Baloxavir marboxil studies for influenza also show that treatment delay is critical — *Ikematsu et al.* report an 86% reduction in cases for post-exposure prophylaxis, *Hayden et al.* show a 33 hour reduction in the time to alleviation of symptoms for treatment within 24 hours and a reduction of 13 hours for treatment within 24-48 hours, and *Kumar et al.* report only 2.5 hours improvement for inpatient treatment.

Treatment delay	Result
Post-exposure prophylaxis	86% fewer cases[87]
<24 hours	-33 hours symptoms[88]
24-48 hours	-13 hours symptoms[88]
Inpatients	-2.5 hours to improvement[89]

Table 4. **Studies of baloxavir marboxil for influenza show that early treatment is more effective.**

Figure 20 shows a mixed-effects meta-regression for efficacy as a function of treatment delay in COVID-19 studies from 172 treatments, showing that efficacy declines rapidly with treatment delay. Early treatment is critical for COVID-19.



Figure 20. **Early treatment is more effective.** Meta-regression showing efficacy as a function of treatment delay in COVID-19 studies from 172 treatments.

Patient demographics

Details of the patient population including age and comorbidities may critically affect how well a treatment works. For example, many COVID-19 studies with relatively young low-comorbidity patients show all patients recovering quickly with or without treatment. In such cases, there is little room for an effective treatment to improve results, for example as in *López-Medina et al.*

SARS-CoV-2 variants

Efficacy may depend critically on the distribution of SARS-CoV-2 variants encountered by patients. Risk varies significantly across variants[91], for example the Gamma variant shows significantly different characteristics[92-95]. Different mechanisms of action may be more or less effective depending on variants, for example the degree to which TMPRSS2 contributes to viral entry can differ across variants[96,97].

Treatment regimen

Effectiveness may depend strongly on the dosage and treatment regimen.

Medication quality

The quality of medications may vary significantly between manufacturers and production batches, which may significantly affect efficacy and safety. *Williams et al.* analyze ivermectin from 11 different sources, showing highly variable antiparasitic efficacy across different manufacturers. *Xu et al.* analyze a treatment from two different manufacturers, showing 9 different impurities, with significantly different concentrations for each manufacturer. Non-prescription supplements may show very wide variations in quality[1,2].

Other treatments

The use of other treatments may significantly affect outcomes, including supplements, other medications, or other interventions such as prone positioning. Treatments may be synergistic[100-116], therefore efficacy may depend strongly on combined treatments.

Effect measured

Across all studies there is a strong association between different outcomes, for example improved recovery is strongly associated with lower mortality. However, efficacy may differ depending on the effect measured, for example a treatment may be more effective against secondary complications and have minimal effect on viral clearance.

Meta analysis

The distribution of studies will alter the outcome of a meta analysis. Consider a simplified example where everything is equal except for the treatment delay, and effectiveness decreases to zero or below with increasing delay. If there are many studies using very late treatment, the outcome may be negative, even though early treatment is very effective. All meta analyses combine heterogeneous studies, varying in population, variants, and potentially all factors above, and therefore may obscure efficacy by including studies where treatment is less effective. Generally, we expect the estimated effect size from meta analysis to be less than that for the optimal case. Looking at all studies is valuable for providing an overview of all research, important to avoid cherry-picking, and informative when a positive result is found despite combining less-optimal situations. However, the resulting estimate does not apply to specific cases such as early treatment in high-risk populations. While we present results for all studies, we also present treatment time and individual outcome analyses, which may be more informative for specific use cases.

Pooled Effects

Pooled effects are no longer required to show efficacy as of August 2021

This section validates the use of pooled effects for COVID-19, which enables earlier detection of efficacy, however pooled effects are no longer required for melatonin as of August 2021. Efficacy is now known based on specific outcomes. Efficacy based on specific outcomes was delayed by 8.0 months compared to using pooled outcomes.

Combining studies is required

For COVID-19, delay in clinical results translates into additional death and morbidity, as well as additional economic and societal damage. Combining the results of studies reporting different outcomes is required. There may be no mortality in a trial with low-risk patients, however a reduction in severity or improved viral clearance may translate into lower mortality in a high-risk population. Different studies may report lower severity, improved recovery, and lower mortality, and the significance may be very high when combining the results. *"The studies reported different outcomes"* is not a good reason for disregarding results. Pooling the results of studies reporting different outcomes allows us to use more of the available information. Logically we should, and do, use additional information when evaluating treatments—for example dose-response and treatment delay-response relationships provide additional evidence of efficacy that is considered when reviewing the evidence for a treatment.

Specific outcome and pooled analyses

We present both specific outcome and pooled analyses. In order to combine the results of studies reporting different outcomes we use the most serious outcome reported in each study, based on the thesis that improvement in the most serious outcome provides comparable measures of efficacy for a treatment. A critical advantage of this

approach is simplicity and transparency. There are many other ways to combine evidence for different outcomes, along with additional evidence such as dose-response relationships, however these increase complexity.

Ethical and practical issues limit high-risk trials

Trials with high-risk patients may be restricted due to ethics for treatments that are known or expected to be effective, and they increase difficulty for recruiting. Using less severe outcomes as a proxy for more serious outcomes allows faster and safer collection of evidence.

Validating pooled outcome analysis for COVID-19

For many COVID-19 treatments, a reduction in mortality logically follows from a reduction in hospitalization, which follows from a reduction in symptomatic cases, which follows from a reduction in PCR positivity. We can directly test this for COVID-19.

Analysis of the the association between different outcomes across studies from all 172 treatments we cover confirms the validity of pooled outcome analysis for COVID-19. Figure 21 shows that lower hospitalization is very strongly associated with lower mortality ($p < 0.000000000001$). Similarly, Figure 22 shows that improved recovery is very strongly associated with lower mortality ($p < 0.000000000001$). Considering the extremes, *Singh et al.* show an association between viral clearance and hospitalization or death, with $p = 0.003$ after excluding one large outlier from a mutagenic treatment, and based on 44 RCTs including 52,384 patients. Figure 23 shows that improved viral clearance is strongly associated with fewer serious outcomes. The association is very similar to *Singh et al.*, with higher confidence due to the larger number of studies. As with *Singh et al.*, the confidence increases when excluding the outlier treatment, from $p = 0.000000082$ to $p = 0.0000000033$.



Figure 21. **Lower hospitalization is associated with lower mortality, supporting pooled outcome analysis.**



Figure 22. Improved recovery is associated with lower mortality, supporting pooled outcome analysis.



Figure 21. Improved viral clearance is associated with fewer serious outcomes, supporting pooled outcome analysis.

Pooled outcomes identify efficacy 5 months faster (7 months for RCTs)

Currently, 55 of the treatments we analyze show statistically significant efficacy or harm, defined as ≥10% decreased risk or >0% increased risk from ≥3 studies. 88% of these have been confirmed with one or more specific outcomes, with a mean delay of 4.9 months. When restricting to RCTs only, 57% of treatments showing statistically significant efficacy/harm with pooled effects have been confirmed with one or more specific outcomes, with a mean delay of 7.3 months. Figure 24 shows when treatments were found effective during the pandemic. Pooled outcomes often resulted in earlier detection of efficacy.



Figure 24. **The time when studies showed that treatments were effective, defined as statistically significant improvement of ≥10% from ≥3 studies.** Pooled results typically show efficacy earlier than specific outcome results. Results from all studies often shows efficacy much earlier than when restricting to RCTs. Results reflect conditions as used in trials to date, these depend on the population treated, treatment delay, and treatment regimen.

Limitations

Pooled analysis could hide efficacy, for example a treatment that is beneficial for late stage patients but has no effect on viral clearance may show no efficacy if most studies only examine viral clearance. In practice, it is rare for a non-antiviral treatment to report viral clearance and to not report clinical outcomes; and in practice other sources of heterogeneity such as difference in treatment delay is more likely to hide efficacy.

Summary

Analysis validates the use of pooled effects and shows significantly faster detection of efficacy on average. However, as with all meta analyses, it is important to review the different studies included. We also present individual outcome analyses, which may be more informative for specific use cases.

Discussion

Publication bias

Publishing is often biased towards positive results, however evidence suggests that there may be a negative bias for inexpensive treatments for COVID-19. Both negative and positive results are very important for COVID-19, media in many countries prioritizes negative results for inexpensive treatments (inverting the typical incentive for scientists that

value media recognition), and there are many reports of difficulty publishing positive results [118-121]. For melatonin, there is currently not enough data to evaluate publication bias with high confidence.

One method to evaluate bias is to compare prospective vs. retrospective studies. Prospective studies are more likely to be published regardless of the result, while retrospective studies are more likely to exhibit bias. For example, researchers may perform preliminary analysis with minimal effort and the results may influence their decision to continue. Retrospective studies also provide more opportunities for the specifics of data extraction and adjustments to influence results.

Figure 25 shows a scatter plot of results for prospective and retrospective studies. 75% of retrospective studies report a statistically significant positive effect for one or more outcomes, compared to 36% of prospective studies, consistent with a bias toward publishing positive results. The median effect size for retrospective studies is 48% improvement, compared to 48% for prospective studies, showing similar results.



Figure 25. **Prospective vs. retrospective studies. The diamonds show the results of random effects meta-analysis.**

Late treatment bias

Studies for melatonin were mostly late treatment studies, in contrast with typical high-profit drugs that were more likely to be tested with early treatment.



Figure 26. **Early treatment was more common for high-profit drugs.**

Funnel plot analysis

Funnel plots have traditionally been used for analyzing publication bias. This is invalid for COVID-19 acute treatment trials — the underlying assumptions are invalid, which we can demonstrate with a simple example. Consider a set of hypothetical perfect trials with no bias. Figure 27 plot A shows a funnel plot for a simulation of 80 perfect trials, with random group sizes, and each patient's outcome randomly sampled (10% control event probability, and a 30% effect size for treatment). Analysis shows no asymmetry ($p > 0.05$). In plot B, we add a single typical variation in COVID-19 treatment trials — treatment delay. Consider that efficacy varies from 90% for treatment within 24 hours, reducing to 10% when treatment is delayed 3 days. In plot B, each trial's treatment delay is randomly selected. Analysis now shows highly significant asymmetry, $p < 0.0001$, with six variants of Egger's test all showing $p < 0.05$ [122-129]. Note that these tests fail even though treatment delay is uniformly distributed. In reality treatment delay is more complex — each trial has a different distribution of delays across patients, and the distribution across trials may be biased (e.g., late treatment trials may be more common). Similarly, many other variations in trials may produce asymmetry, including dose, administration, duration of treatment, differences in SOC, comorbidities, age, variants, and bias in design, implementation, analysis, and reporting.



Figure 27. **Example funnel plot analysis for simulated perfect trials.**

Conflicts of interest

Pharmaceutical drug trials often have conflicts of interest whereby sponsors or trial staff have a financial interest in the outcome being positive. Melatonin for COVID-19 lacks this because it is an inexpensive and widely available supplement. In contrast, most COVID-19 melatonin trials have been run by physicians on the front lines with the primary goal of finding the best methods to save human lives and minimize the collateral damage caused by COVID-19. While pharmaceutical companies are careful to run trials under optimal conditions (for example, restricting patients to those most likely to benefit, only including patients that can be treated soon after onset when necessary, and ensuring accurate dosing), not all melatonin trials represent the optimal conditions for efficacy.

Limitations

Summary statistics from meta analysis necessarily lose information. As with all meta analyses, studies are heterogeneous, with differences in treatment delay, treatment regimen, patient demographics, variants, conflicts of interest, standard of care, and other factors. We provide analyses for specific outcomes and by treatment delay, and we aim to identify key characteristics in the forest plots and summaries. Results should be viewed in the context of study characteristics.

Some analyses classify treatment based on early or late administration, as done here, while others distinguish between mild, moderate, and severe cases. Viral load does not indicate degree of symptoms — for example patients may have a high viral load while being asymptomatic. With regard to treatments that have antiviral properties, timing of treatment is critical — late administration may be less helpful regardless of severity.

Details of treatment delay per patient is often not available. For example, a study may treat 90% of patients relatively early, but the events driving the outcome may come from 10% of patients treated very late. Our 5 day cutoff for early treatment may be too conservative, 5 days may be too late in many cases.

Comparison across treatments is confounded by differences in the studies performed, for example dose, variants, and conflicts of interest. Trials with conflicts of interest may use designs better suited to the preferred outcome.

In some cases, the most serious outcome has very few events, resulting in lower confidence results being used in pooled analysis, however the method is simpler and more transparent. This is less critical as the number of studies increases. Restriction to outcomes with sufficient power may be beneficial in pooled analysis and improve accuracy when there are few studies, however we maintain our pre-specified method to avoid any retrospective changes.

Studies show that combinations of treatments can be highly synergistic and may result in many times greater efficacy than individual treatments alone [100-116]. Therefore standard of care may be critical and benefits may diminish or disappear if standard of care does not include certain treatments.

This real-time analysis is constantly updated based on submissions. Accuracy benefits from widespread review and submission of updates and corrections from reviewers. Less popular treatments may receive fewer reviews.

No treatment or intervention is 100% available and effective for all current and future variants. Efficacy may vary significantly with different variants and within different populations. All treatments have potential side effects. Propensity to experience side effects may be predicted in advance by qualified physicians. We do not provide medical advice. Before taking any medication, consult a qualified physician who can compare all options, provide personalized advice, and provide details of risks and benefits based on individual medical history and situations.

Notes

2 of 19 studies combine treatments. The results of melatonin alone may differ. 1 of 9 RCTs use combined treatment. 7 other meta analyses show significant improvements with melatonin for mortality [4-7], mechanical ventilation [8], hospitalization [6,8], clinical improvement [8], and recovery [9,10].

Reviews

Many reviews cover melatonin for COVID-19, presenting additional background on mechanisms and related results, including [43,54,58,69,130-148].

Other studies

Additional preclinical or review papers suggesting potential benefits of melatonin for COVID-19 include [168-189]. We have not reviewed these studies in detail.

Perspective

Results compared with other treatments

SARS-CoV-2 infection and replication involves a complex interplay of 100+ host and viral proteins and other factors [31-38], providing many therapeutic targets. Over 9,000 compounds have been predicted to reduce COVID-19 risk [39], either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications. Figure 28 shows an overview of the results for melatonin in the context of multiple COVID-19 treatments, and Figure 29 shows a plot of efficacy vs. cost for COVID-19 treatments.



Figure 28. **Scatter plot showing results within the context of multiple COVID-19 treatments.** Diamonds shows the results of random effects meta-analysis. 0.6% of 9,000+ proposed treatments show efficacy [190].



Figure 29. **Efficacy vs. cost for COVID-19 treatments.**

Conclusion

Melatonin is an effective treatment for COVID-19. Significantly lower risk is seen for mortality, ventilation, and recovery. 10 studies from 10 independent teams in 6 countries show significant benefit. Meta analysis using the most serious outcome reported shows 43% [31-54%] lower risk. Results are similar for higher quality studies and slightly worse for Randomized Controlled Trials and peer-reviewed studies. Early treatment is more effective than late treatment.

7 other meta analyses show significant improvements with melatonin for mortality[4-7], mechanical ventilation[8], hospitalization[6,8], clinical improvement[8], and recovery[9,10].

Study Notes

Alizadeh



Small RCT 31 mild/moderate COVID-19 outpatients in Iran, 14 treated with melatonin, showing improved recovery with treatment.

Alizadeh



RCT 67 extremely late stage intubated patients in Iran, showing lower CRP with melatonin treatment, but no significant difference in outcomes.

Ameri



RCT 226 ICU patients in Iran, showing lower mortality with melatonin treatment.

Bologna



Retrospective 40 hospitalized patients in Italy treated with melatonin and 40 control patients, showing improved sleep, reduced delirium, shorter hospitalization and oxygen times, and reduced ICU admission and mortality (not statistically significant).

Boukef

150 patient melatonin early treatment RCT with results not reported over 2 years after completion.

Darban



Small RCT in Iran with 20 ICU patients, 10 treated with high-dose vitamin C, melatonin, and zinc, not showing significant differences.

Farnoosh



RCT 44 hospitalized patients in Iran, 24 treated with melatonin, showing faster recovery with treatment. There was no mortality.

Fernandez-Tresguerres

335 patient melatonin late treatment study with results not reported over 3 years after completion.

Fogleman



Early terminated low-risk patient RCT with 32 low-dose vitamin C, 32 melatonin, and 34 placebo patients, showing faster resolution of symptoms with melatonin in spline regression analysis, and no significant difference for vitamin C. All patients recovered with no serious outcomes reported. Baseline symptoms scores were higher in the melatonin and vitamin C arms (median 27 and 24 vs. 18 for placebo).

García-García



García-García PrEP RCT healthcare workers in Spain, showing no significant difference in cases with melatonin prophylaxis. Most cases were asymptomatic or paucisymtomatic, there were two symptomatic cases, no moderate/severe cases, and no hospitalization.

The registered primary outcome is symptomatic cases. Authors report on all cases due to the small number of symptomatic cases. They did not include the original primary outcome results in the paper, but have provided the results via email to a contributor.

The dosage in this trial is very low, 2mg daily. Meta regression suggests higher doses are much more effective. EudraCT 2020-001530-35.

Hasan



RCT 158 severe condition patients in Iraq, 82 treated with melatonin, showing lower mortality, thrombosis, and sepsis with treatment.

Hosseini



40 hospitalized patients in Iran, 20 treated with melatonin, showing faster recovery and attenuated inflammatory cytokines with treatment.

Jehi



Retrospective 11,672 patients tested for COVID-19 with 818 testing positive, showing significantly lower risk with melatonin use.

Karimpour-razkenari



Retrospective 31 ICU patients, 12 treated with melatonin, showing lower mortality with treatment, without statistical significance. Melatonin 15mg daily.

Lissoni



Small study with 30 patients treated with melatonin, cannabidiol, and for 14 patients angiotensin 1-7, compared with an age/sex matched control group during the same period, showing lower hospitalization with treatment.

Mousavi



RCT 96 hospitalized patients in Iran, 48 treated with melatonin, showing improved sleep quality and SpO2 with treatment. 3mg oral melatonin daily. Authors recommend studies with a higher dose. IRCT20200411047030N1.

Oral

228 patient melatonin study with results not reported over 3 years after completion.

Piovezan

Estimated 100 patient melatonin late treatment RCT with results not reported over 4 years after estimated completion.

Ramlall



Retrospective 948 intubated patients, 196 treated with melatonin, showing lower mortality with treatment.

Rodríguez-Rubio

18 patient melatonin late treatment RCT with results not reported over 4 years after completion.

Sánchez-González



Retrospective 2,463 hospitalized patients in Spain, 265 treated with melatonin, showing lower mortality with treatment in PSM analysis, however these results are subject to immortal time bias. Authors excluded from the sample patients that died during the first 72 hours of admission without taking melatonin, and patients that started on melatonin in the last 7 days of their admittance, having completed 75% of their stay.

Sánchez-Rico



Retrospective database analysis in France with 272 patients treated with melatonin, showing 19% lower mortality after adjustments, without statistical significance. Risk was lower for higher dosage (not statistically significant). Age was only in three age ranges and severe COVID was binary, likely leading to substantial residual confounding. Unadjusted differences were extreme with 60% >80 years old for melatonin compared to 15% for control. Mean daily dose 2.61mg. The title of the paper is incorrect, the most adjusted results show melatonin did reduce mortality (without reaching statistical significance).

Tian



PSM retrospective 1,066 ICU patients in China, showing significantly lower mortality with ramelteon treatment.

Zhou



PSM observational study with a database of 26,779 patients in the USA, showing significantly lower risk of PCR+ with melatonin usage.

Appendix 1. Methods and Data

We perform ongoing searches of PubMed, medRxiv, Europe PMC, ClinicalTrials.gov, The Cochrane Library, Google Scholar, Research Square, ScienceDirect, Oxford University Press, the reference lists of other studies and meta-analyses, and submissions to the site c19early.org. Search terms are melatonin and COVID-19 or SARS-CoV-2. Automated searches are performed twice daily, with all matches reviewed for inclusion. All studies regarding the use of melatonin for COVID-19 that report a comparison with a control group are included in the main analysis. Sensitivity analysis is performed, excluding studies with major issues, epidemiological studies, and studies with minimal available information. Studies with major unexplained data issues, for example major outcome data that is impossible to be correct with no response from the authors, are excluded. This is a living analysis and is updated regularly.

We extracted effect sizes and associated data from all studies. If studies report multiple kinds of effects then the most serious outcome is used in pooled analysis, while other outcomes are included in the outcome specific analyses. For example, if effects for mortality and cases are reported then they are both used in specific outcome analyses, while mortality is used for pooled analysis. If symptomatic results are reported at multiple times, we use the latest time, for example if mortality results are provided at 14 days and 28 days, the results at 28 days have preference. Mortality alone is preferred over combined outcomes. Outcomes with zero events in both arms are not used, the next most serious outcome with one or more events is used. For example, in low-risk populations with no mortality, a reduction in mortality with treatment is not possible, however a reduction in hospitalization, for example, is still valuable. Clinical outcomes are considered more important than viral outcomes. When basically all patients recover in both treatment and control groups, preference for viral clearance and recovery is given to results mid-recovery where available. After most or all patients have recovered there is little or no room for an effective treatment to do better, however faster recovery is valuable. An IPD meta-analysis confirms that intermediate viral load reduction is more

closely associated with hospitalization/death than later viral load reduction [191]. If only individual symptom data is available, the most serious symptom has priority, for example difficulty breathing or low SpO_2 is more important than cough. When results provide an odds ratio, we compute the relative risk when possible, or convert to a relative risk according to *Zhang (B) et al.* Reported confidence intervals and *p*-values are used when available, and adjusted values are used when provided. If multiple types of adjustments are reported propensity score matching and multivariable regression has preference over propensity score matching or weighting, which has preference over multivariable regression. Adjusted results have preference over unadjusted results for a more serious outcome when the adjustments significantly alter results. When needed, conversion between reported *p*-values and confidence intervals followed *Altman, Altman (B)*, and Fisher's exact test was used to calculate *p*-values for event data. If continuity correction for zero values is required, we use the reciprocal of the opposite arm with the sum of the correction factors equal to 1 [195]. Results are expressed with RR < 1.0 favoring treatment, and using the risk of a negative outcome when applicable (for example, the risk of death rather than the risk of survival). If studies only report relative continuous values such as relative times, the ratio of the time for the treatment group versus the time for the control group is used. Calculations are done in Python (3.13.5) with scipy (1.16.0), pythonmeta (1.26), numpy (2.3.1), statsmodels (0.14.4), and plotly (6.2.0).



Figure 30. **Mid-recovery results can more accurately reflect efficacy when almost all patients recover.** *Mateja et al.* **confirm that intermediate viral load results more accurately reflect hospitalization/death.**

Forest plots are computed using PythonMeta [196] with the DerSimonian and Laird random effects model (the fixed effect assumption is not plausible in this case) and inverse variance weighting. Results are presented with 95% confidence intervals. Heterogeneity among studies was assessed using the I^2 statistic. Mixed-effects meta-regression results are computed with R (4.4.0) using the metafor (4.6-0) and rms (6.8-0) packages, and using the most serious sufficiently powered outcome. For all statistical tests, a *p*-value less than 0.05 was considered statistically significant. Grobid 0.8.2 is used to parse PDF documents.

We have classified studies as early treatment if most patients are not already at a severe stage at the time of treatment (for example based on oxygen status or lung involvement), and treatment started within 5 days of the onset of symptoms. If studies contain a mix of early treatment and late treatment patients, we consider the treatment time of patients contributing most to the events (for example, consider a study where most patients are treated early but late treatment patients are included, and all mortality events were observed with late treatment patients). We note that a shorter time may be preferable. Antivirals are typically only considered effective when used within a shorter timeframe, for example 0-36 or 0-48 hours for oseltamivir, with longer delays not being effective [85,86].

We received no funding, this research is done in our spare time. We have no affiliations with any pharmaceutical companies or political parties.

A summary of study results is below. Please submit updates and corrections at https://c19early.org/jmeta.html.

Early treatment

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

Alizadeh (B), 5/29/2021, Single Blind Randomized Controlled Trial, Iran, peer-reviewed, 6 authors, study period 30 June, 2020 - 5 August, 2020.	risk of no recovery, 73.0% lower, RR 0.27, *p* = 0.06, treatment 2 of 14 (14.3%), control 9 of 17 (52.9%), NNT 2.6, day 14.
Boukef, 2/28/2023, Double Blind Randomized Controlled Trial, placebo-controlled, Tunisia, trial NCT05670444 (history).	150 patient RCT with results unknown and over 2 years late.

Lissoni, 12/30/2020, prospective, Italy, peer-reviewed, 14 authors, this trial uses multiple treatments in the treatment arm (combined with cannabidiol and angiotensin 1-7) - results of individual treatments may vary.	risk of hospitalization, 90.9% lower, RR 0.09, $p = 0.05$, treatment 0 of 30 (0.0%), control 5 of 30 (16.7%), NNT 6.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).

Late treatment

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

Alizadeh, 5/13/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 11 authors, study period June 2020 - September 2020, excluded in exclusion analyses: extremely late treatment, over 75% control mortality.	risk of death, 3.8% lower, RR 0.96, $p = 0.73$, treatment 28 of 33 (84.8%), control 30 of 34 (88.2%), NNT 30.
	risk of no extubation, 13.6% lower, RR 0.86, $p = 0.19$, treatment 26 of 33 (78.8%), control 31 of 34 (91.2%), NNT 8.1.
	ventilation time, 27.0% lower, relative time 0.73, $p = 0.09$, treatment 33, control 34.
Ameri, 11/19/2022, Randomized Controlled Trial, Iran, peer-reviewed, 9 authors, study period 1 March, 2021 - 30 November, 2021.	risk of death, 28.8% lower, RR 0.71, $p < 0.001$, treatment 73 of 109 (67.0%), control 110 of 117 (94.0%), NNT 3.7, primary outcome.
	risk of mechanical ventilation, 27.6% lower, RR 0.72, $p = 0.003$, treatment 56 of 109 (51.4%), control 83 of 117 (70.9%), NNT 5.1, primary outcome.
	clinical status, 25.0% lower, RR 0.75, $p = 0.001$, treatment 109, control 117, day 14.
	recovery time, 25.0% lower, relative time 0.75, $p = 0.04$, treatment 109, control 117.
	hospitalization time, 28.6% lower, relative time 0.71, $p = 0.03$, treatment 109, control 117.
Bologna, 12/14/2021, retrospective, Italy, peer-reviewed, 3 authors.	risk of death, 50.0% lower, RR 0.50, $p = 0.48$, treatment 3 of 40 (7.5%), control 6 of 40 (15.0%), NNT 13.
	risk of ICU admission, 50.0% lower, RR 0.50, $p = 0.48$, treatment 3 of 40 (7.5%), control 6 of 40 (15.0%), NNT 13.
	hospitalization time, 8.7% lower, relative time 0.91, $p = 0.05$, treatment mean 31.3 (±6.8) n=40, control mean 34.3 (±6.9) n=40.
	relative sub-intensive hospitalization time, 38.8% better, relative time 0.61, $p < 0.001$, treatment mean 12.3 (±3.0) n=40, control mean 20.1 (±6.1) n=40.
	relative NIV time, 58.4% better, relative time 0.42, $p < 0.001$, treatment mean 5.2 (±3.0) n=40, control mean 12.5 (±4.2) n=40.
	relative high flow oxygen time, 7.8% better, relative time 0.92, $p = 0.35$, treatment mean 7.1 (±2.5) n=40, control mean 7.7 (±3.2) n=40.
	relative sleep time, 18.2% better, RR 0.82, $p < 0.001$, treatment mean 5.5 (±0.8) n=40, control mean 4.5 (±1.2) n=40.

	delirium, 33.3% lower, RR 0.67, $p < 0.001$, treatment mean 2.2 (±1.1) n=40, control mean 3.3 (±1.3) n=40.
Darban, 12/15/2020, Randomized Controlled Trial, Iran, peer-reviewed, 8 authors, study period 7 April, 2020 - 8 June, 2020, this trial uses multiple treatments in the treatment arm (combined with vitamin C and zinc) - results of individual treatments may vary, trial IRCT20151228025732N52.	risk of progression, 33.3% lower, RR 0.67, $p = 1.00$, treatment 2 of 10 (20.0%), control 3 of 10 (30.0%), NNT 10.
	ICU time, 6.0% lower, relative time 0.94, $p = 0.30$, treatment 10, control 10.
Farnoosh, 6/23/2021, Double Blind Randomized Controlled Trial, Iran, peer-reviewed, 12 authors, study period 25 April, 2020 - 5 June, 2020, average treatment delay 7.0 days.	risk of ICU admission, 81.5% lower, RR 0.19, $p = 0.20$, treatment 0 of 24 (0.0%), control 2 of 20 (10.0%), NNT 10.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
	recovery time, 49.0% lower, relative time 0.51, $p = 0.004$, treatment 24, control 20.
	risk of no hospital discharge, 44.4% lower, RR 0.56, $p = 0.65$, treatment 2 of 24 (8.3%), control 3 of 20 (15.0%), NNT 15.
	time to discharge, 42.9% lower, relative time 0.57, $p = 0.02$, treatment 24, control 20.
Fernandez-Tresguerres, 3/31/2022, Spain, trial NCT05596617 (history).	335 patient study with results unknown and over 3 years late.
Fogleman, 7/27/2022, Double Blind Randomized Controlled Trial, placebo-controlled, USA, peer-reviewed, mean age 52.0, 7 authors, study period 5 October, 2020 - 21 June, 2021, average treatment delay 6.0 days, trial NCT04530539 (history).	relative recovery, 17.3% better, RR 0.83, $p = 0.38$, treatment mean 20.33 (±16.4) n=32, control mean 16.82 (±15.7) n=34, mid-recovery, relative symptom improvement, day 9.
Hasan, 10/12/2021, Randomized Controlled Trial, Iraq, peer-reviewed, 3 authors, study period 1 December, 2020 - 1 June, 2021.	risk of death, 92.9% lower, RR 0.07, $p < 0.001$, treatment 1 of 82 (1.2%), control 13 of 76 (17.1%), NNT 6.3.
Hosseini, 5/17/2021, prospective, Iran, peer-reviewed, 9 authors.	recovery time, 47.6% lower, relative time 0.52, $p = 0.001$, treatment 20, control 20.
Karimpour-razkenari, 3/10/2022, retrospective, Iran, peer-reviewed, 6 authors, study period 13 March, 2020 - 30 May, 2020.	risk of death, 39.0% lower, HR 0.61, $p = 0.37$, treatment 5 of 12 (41.7%), control 13 of 19 (68.4%), NNT 3.7, Kaplan–Meier.
	ventilation time, 42.9% lower, relative time 0.57, $p = 0.13$, treatment 12, control 19.
	ICU time, 1.9% lower, relative time 0.98, $p = 0.85$, treatment 12, control 19.
Mousavi, 8/30/2021, Randomized Controlled Trial, Iran, peer-reviewed, 7 authors, study period 14 April, 2020 - 15 June, 2020.	risk of death, 66.7% lower, RR 0.33, $p = 0.62$, treatment 1 of 48 (2.1%), control 3 of 48 (6.2%), NNT 24, day 10.
	risk of ICU admission, 40.0% lower, RR 0.60, $p = 0.41$, treatment 6 of 48 (12.5%), control 10 of 48 (20.8%), NNT 12, day 10.
Piovezan, 3/1/2021, Double Blind Randomized Controlled Trial, placebo-controlled, Brazil, trial NCT04470297 (history) (MELCOV2020).	Estimated 100 patient RCT with results unknown and over 4 years late.
Ramlall, 10/18/2020, retrospective, USA, preprint, 3 authors.	risk of death, 86.9% lower, HR 0.13, $p < 0.001$, treatment 196, control 752, adjusted per study, multivariable, Cox proportional hazards.

Rodríguez-Rubio, 8/5/2020, Double Blind Randomized Controlled Trial, placebo-controlled, Spain, trial NCT04568863 (history) (MELCOVID).	18 patient RCT with results unknown and over 4 years late.
Sánchez-González, 7/20/2021, retrospective, Spain, peer-reviewed, 4 authors, excluded in exclusion analyses: immortal time bias may significantly affect results.	risk of death, 54.4% lower, RR 0.46, $p < 0.001$, treatment 24 of 224 (10.7%), control 53 of 224 (23.7%), NNT 7.7, odds ratio converted to relative risk, PSM.
Sánchez-Rico, 2/5/2022, retrospective, France, peer-reviewed, 6 authors, study period 24 January, 2020 - 31 October, 2021.	risk of death, 19.0% lower, RR 0.81, $p = 0.15$, treatment 82 of 272 (30.1%), control 6,487 of 58,290 (11.1%), adjusted per study, model b.
Tian, 5/19/2025, retrospective, China, peer-reviewed, 3 authors.	risk of death, 47.0% lower, HR 0.53, $p = 0.005$, treatment 301, control 301, adjusted per study, propensity score matching, multivariable, ramelteon.

Prophylaxis

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

García-García, 2/21/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Spain, peer-reviewed, 25 authors, study period April 2020 - December 2020, trial NCT04353128 (history) (MeCOVID).	risk of symptomatic case, 7.4% lower, RR 0.93, $p = 1.00$, treatment 1 of 163 (0.6%), control 1 of 151 (0.7%), NNT 2051, primary outcome.
	risk of case, 108.4% higher, RR 2.08, $p = 0.26$, treatment 9 of 163 (5.5%), control 4 of 151 (2.6%), post-hoc primary outcome.
Jehi, 6/10/2020, retrospective, USA, peer-reviewed, 8 authors.	risk of case, 58.0% lower, RR 0.42, $p < 0.001$, treatment 16 of 529 (3.0%), control 802 of 11,143 (7.2%), NNT 24, development cohort.
	risk of case, 99.7% lower, RR 0.003, $p = 0.09$, treatment 0 of 18 (0.0%), control 290 of 2,005 (14.5%), NNT 6.9, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), Florida validation cohort.
Zhou, 11/6/2020, retrospective, propensity score matching, USA, peer-reviewed, 18 authors.	risk of case, 21.1% lower, RR 0.79, $p = 0.01$, treatment 222 of 1,055 (21.0%), control 8,052 of 25,724 (31.3%), NNT 9.7, odds ratio converted to relative risk, PSM.

Supplementary Data

Supplementary Data

Footnotes

a. Viral infection and replication involves attachment, entry, uncoating and release, genome replication and transcription, translation and protein processing, assembly and budding, and release. Each step can be disrupted by therapeutics.

References

1. **Crawford** et al., *Analysis of Select Dietary Supplement Products Marketed to Support or Boost the Immune System*, JAMA Network Open, doi:10.1001/jamanetworkopen.2022.26040.
2. **Crighton** et al., *Toxicological screening and DNA sequencing detects contamination and adulteration in regulated herbal medicines and supplements for diet, weight loss and cardiovascular health*, Journal of Pharmaceutical and Biomedical Analysis, doi:10.1016/j.jpba.2019.112834.
3. **Chanyandura** et al., *Evaluation of The Pharmaceutical Quality of the Most Commonly Purchased Vitamin C (Ascorbic Acid) Formulations in COVID-19 Infection in South Africa*, J. Basic Appl. Pharm. Sci., doi:10.33790/jbaps1100105.
4. **Pilia** et al., *Does melatonin reduce mortality in COVID-19?*, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103817.
5. **Tóth** et al., *Melatonin as adjuvant treatment in COVID-19 patients. A meta-analysis of randomized and propensity matched studies*, Signa Vitae, doi:10.22514/sv.2023.076.
6. **Amin** et al., *Role of Melatonin in Management of COVID-19: A Systematic Review*, Microbes, Infection and Chemotherapy, doi:10.54034/mic.e1982.
7. **Qin** et al., *Benefits of melatonin on mortality in severe-to-critical COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials*, Clinics, doi:10.1016/j.clinsp.2025.100638.
8. **Taha** et al., *Safety and efficacy of melatonin as an adjuvant therapy in COVID-19 patients: Systematic review and meta-analysis*, Advances in Medical Sciences, doi:10.1016/j.advms.2023.09.007.
9. **Lan** et al., *Efficacy of Melatonin in the Treatment of Patients With COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials*, Journal of Medical Virology, doi:10.1002/jmv.27595.
10. **Wang** et al., *The safety and efficacy of melatonin in the treatment of COVID-19: A systematic review and meta-analysis*, Medicine, doi:10.1097/MD.0000000000030874.
11. **Ryu** et al., *Fibrin drives thromboinflammation and neuropathology in COVID-19*, Nature, doi:10.1038/s41586-024-07873-4.
12. **Rong** et al., *Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19*, Cell Host & Microbe, doi:10.1016/j.chom.2024.11.007.
13. **Yang** et al., *SARS-CoV-2 infection causes dopaminergic neuron senescence*, Cell Stem Cell, doi:10.1016/j.stem.2023.12.012.
14. **Scardua-Silva** et al., *Microstructural brain abnormalities, fatigue, and cognitive dysfunction after mild COVID-19*, Scientific Reports, doi:10.1038/s41598-024-52005-7.
15. **Hampshire** et al., *Cognition and Memory after Covid-19 in a Large Community Sample*, New England Journal of Medicine, doi:10.1056/NEJMoa2311330.
16. **Duloquin** et al., *Is COVID-19 Infection a Multiorganic Disease? Focus on Extrapulmonary Involvement of SARS-CoV-2*, Journal of Clinical Medicine, doi:10.3390/jcm13051397.
17. **Sodagar** et al., *Pathological Features and Neuroinflammatory Mechanisms of SARS-CoV-2 in the Brain and Potential Therapeutic Approaches*, Biomolecules, doi:10.3390/biom12070971.
18. **Sagar** et al., *COVID-19-associated cerebral microbleeds in the general population*, Brain Communications, doi:10.1093/braincomms/fcae127.
19. **Verma** et al., *Persistent Neurological Deficits in Mouse PASC Reveal Antiviral Drug Limitations*, bioRxiv, doi:10.1101/2024.06.02.596989.
20. **Panagea** et al., *Neurocognitive Impairment in Long COVID: A Systematic Review*, Archives of Clinical Neuropsychology, doi:10.1093/arclin/acae042.
21. **Ariza** et al., *COVID-19: Unveiling the Neuropsychiatric Maze—From Acute to Long-Term Manifestations*, Biomedicines, doi:10.3390/biomedicines12061147.
22. **Vashisht** et al., *Neurological Complications of COVID-19: Unraveling the Pathophysiological Underpinnings and Therapeutic Implications*, Viruses, doi:10.3390/v16081183.
23. **Ahmad** et al., *Neurological Complications and Outcomes in Critically Ill Patients With COVID-19: Results From International Neurological Study Group From the COVID-19 Critical Care Consortium*, The Neurohospitalist, doi:10.1177/19418744241292487.
24. **Wang (B)** et al., *SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction*, Translational Neurodegeneration, doi:10.1186/s40035-024-00458-1.
25. **Eberhardt** et al., *SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels*, Nature Cardiovascular Research, doi:10.1038/s44161-023-00336-5.
26. **Van Tin** et al., *Spike Protein of SARS-CoV-2 Activates Cardiac Fibrogenesis through NLRP3 Inflammasomes and NF-κB Signaling*, Cells, doi:10.3390/cells13161331.
27. **Borka Balas** et al., *COVID-19 and Cardiac Implications—Still a Mystery in Clinical Practice*, Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm2405125.
28. **AlTaweel** et al., *An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies*, Archives of Microbiology & Immunology, doi:10.26502/ami.936500177.
29. **Saha** et al., *COVID-19 beyond the lungs: Unraveling its vascular impact and cardiovascular complications—mechanisms and therapeutic implications*, Science Progress, doi:10.1177/00368504251322069.
30. **Trender** et al., *Changes in memory and cognition during the SARS-CoV-2 human challenge study*, eClinicalMedicine, doi:10.1016/j.eclinm.2024.102842.

31. **Dugied** et al., *Multimodal SARS-CoV-2 interactome sketches the virus-host spatial organization*, Communications Biology, doi:10.1038/s42003-025-07933-z.

32. **Malone** et al., *Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design*, Nature Reviews Molecular Cell Biology, doi:10.1038/s41580-021-00432-z.

33. **Murigneux** et al., *Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly*, Nature Communications, doi:10.1038/s41467-024-44958-0.

34. **Lv** et al., *Host proviral and antiviral factors for SARS-CoV-2*, Virus Genes, doi:10.1007/s11262-021-01869-2.

35. **Lui** et al., *Nsp1 facilitates SARS-CoV-2 replication through calcineurin-NFAT signaling*, Virology, doi:10.1128/mbio.00392-24.

36. **Niarakis** et al., *Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches*, Frontiers in Immunology, doi:10.3389/fimmu.2023.1282859.

37. **Katiyar** et al., *SARS-CoV-2 Assembly: Gaining Infectivity and Beyond*, Viruses, doi:10.3390/v16111648.

38. **Wu** et al., *Decoding the genome of SARS-CoV-2: a pathway to drug development through translation inhibition*, RNA Biology, doi:10.1080/15476286.2024.2433830.

39. ***c19early.org***, c19early.org/treatments.html.

40. **Soto** et al., *Redox Homeostasis Alteration Is Restored through Melatonin Treatment in COVID-19 Patients: A Preliminary Study*, International Journal of Molecular Sciences, doi:10.3390/ijms25084543.

41. **Šeškutė** et al., *Antiviral Effect of Melatonin on Caco-2 Cell Organoid Culture: Trick or Treat?*, International Journal of Molecular Sciences, doi:10.3390/ijms252211872.

42. **Fernandes** et al., *Melatonin-Index as a biomarker for predicting the distribution of presymptomatic and asymptomatic SARS-CoV-2 carriers*, Melatonin Research, doi:10.32794/mr11250090.

43. **Xie** et al., *The role of reactive oxygen species in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection-induced cell death*, Cellular & Molecular Biology Letters, doi:10.1186/s11658-024-00659-6.

44. **Behl** et al., *CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target*, Science of The Total Environment, doi:10.1016/j.scitotenv.2021.152072.

45. **Wang (C)** et al., *SARS-CoV-2 invades host cells via a novel route: CD147-spike protein*, bioRxiv, doi:10.1101/2020.03.14.988345.

46. **Su** et al., *Melatonin attenuates angiotensin II-induced cardiomyocyte hypertrophy through the CyPA/CD147 signaling pathway*, Molecular and Cellular Biochemistry, doi:10.1007/s11010-016-2808-9.

47. **Hooper**, P., *COVID-19 and heme oxygenase: novel insight into the disease and potential therapies*, Cell Stress and Chaperones, doi:10.1007/s12192-020-01126-9.

48. **Anderson** et al., *Melatonin: Roles in influenza, Covid-19, and other viral infections*, Reviews in Medical Virology, doi:10.1002/rmv.2109.

49. **Shi** et al., *Melatonin attenuates acute kidney ischemia/reperfusion injury in diabetic rats by activation of the SIRT1/Nrf2/HO-1 signaling pathway*, Bioscience Reports, doi:10.1042/BSR20181614.

50. **Anderson (B)** et al., *Ebola virus: Melatonin as a readily available treatment option*, Journal of Medical Virology, doi:10.1002/jmv.24130.

51. **Hooper (B)**, P., *Heme oxygenase agonists—fluvoxamine, melatonin—are efficacious therapy for Covid-19*, Cell Stress and Chaperones, doi:10.1007/s12192-021-01246-w.

52. **Cecon** et al., *Melatonin drugs inhibit SARS-CoV-2 entry into the brain and virus-induced damage of cerebral small vessels*, bioRxiv, doi:10.1101/2021.12.30.474561.

53. **Cecon (B)** et al., *Therapeutic potential of melatonin and melatonergic drugs on K18-hACE2 mice infected with SARS-CoV-2*, Journal of Pineal Research, doi:10.1111/jpi.12772.

54. **Loh** et al., *Melatonin: Regulation of Viral Phase Separation and Epitranscriptomics in Post-Acute Sequelae of COVID-19*, International Journal of Molecular Sciences, doi:10.3390/ijms23158122.

55. **Sen**, A., *Deficient synthesis of melatonin in COVID-19 can impair the resistance of coronavirus patients to mucormycosis*, OSF Preprints, doi:10.31219/osf.io/xw3np.

56. **Morvaridzadeh** et al., *Effect of melatonin supplementation on oxidative stress parameters: A systematic review and meta-analysis*, Pharmacological Research, doi:10.1016/j.phrs.2020.105210.

57. **Polonikov**, A., *Endogenous Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in COVID-19 Patients*, ACS Infectious Diseases, doi:10.1021/acsinfecdis.0c00288.

58. **Zhang** et al., *COVID-19: Melatonin as a potential adjuvant treatment*, Life Sciences, doi:10.1016/j.lfs.2020.117583.

59. **Miller** et al., *The role of melatonin in immuno-enhancement: potential application in cancer*, International Journal of Experimental Pathology, doi:10.1111/j.0959-9673.2006.00474.x.

60. **Lewis** et al., *Melatonin for the promotion of sleep in adults in the intensive care unit*, Cochrane Database of Systematic Reviews, doi:10.1002/14651858.CD012455.pub2.

61. **Reiter** et al., *Treatment of ebola and other infectious diseases: melatonin "goes viral"*, Melatonin Research, doi:10.32794/mr11250047.

62. **Wu (B)** et al., *Melatonin Alleviates Radiation-Induced Lung Injury via Regulation of miR-30e/NLRP3 Axis*, Oxidative Medicine and Cellular Longevity, doi:10.1155/2019/4087298.

63. **Gitto** et al., *Correlation among cytokines, bronchopulmonary dysplasia and modality of ventilation in preterm newborns: improvement with melatonin treatment*, Journal of Pineal Research, doi:10.1111/j.1600-079X.2005.00251.x.

64. **Gitto (B)** et al., *Oxidative and Inflammatory Parameters in Respiratory Distress Syndrome of Preterm Newborns: Beneficial Effects of Melatonin*, American Journal of

Perinatology, doi:10.1055/s-2004-828610.

65. **Acharya** et al., *Potential therapeutic intervention of melatonin against COVID-19: A comparative pharmacokinetic study*, Melatonin Research, doi:10.32794/mr112500181.

66. **Kumar Yadalam** et al., *Assessing the therapeutic potential of angomelatine, ramelteon, and melatonin against SARS-Cov-2*, Saudi Journal of Biological Sciences, doi:10.1016/j.sjbs.2022.01.049.

67. **Zeraatkar** et al., *Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review*, BMJ Medicine, doi:10.1136/bmjmed-2022-0003091.

68. **Davidson** et al., *No evidence of important difference in summary treatment effects between COVID-19 preprints and peer-reviewed publications: a meta-epidemiological study*, Journal of Clinical Epidemiology, doi:10.1016/j.jclinepi.2023.08.011.

69. **Reiter (B)** et al., *Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection*, Cellular and Molecular Life Sciences, doi:10.1007/s00018-021-04102-3.

70. **Jadad** et al., *Randomized Controlled Trials: Questions, Answers, and Musings, Second Edition*, doi:10.1002/9780470691922.

71. **Gøtzsche**, P., *Bias in double-blind trials*, Doctoral Thesis, University of Copenhagen, www.scientificfreedom.dk/2023/05/16/bias-in-double-blind-trials-doctoral-thesis/.

72. **Als-Nielsen** et al., *Association of Funding and Conclusions in Randomized Drug Trials*, JAMA, doi:10.1001/jama.290.7.921.

73. **c19early.org (B)**, c19early.org/jsupp.html#fig_rctobs.

74. **Concato** et al., NEJM, 342:1887-1892, doi:10.1056/NEJM200006223422507.

75. **Anglemyer** et al., *Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials*, Cochrane Database of Systematic Reviews 2014, Issue 4, doi:10.1002/14651858.MR000034.pub2.

76. **c19early.org (C)**, c19early.org/rctobs.html.

77. **Lee** et al., *Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines*, Arch Intern Med., 2011, 171:1, 18-22, doi:10.1001/archinternmed.2010.482.

78. **Deaton** et al., *Understanding and misunderstanding randomized controlled trials*, Social Science & Medicine, 210, doi:10.1016/j.socscimed.2017.12.005.

79. **Nichol** et al., *Challenging issues in randomised controlled trials*, Injury, 2010, doi: 10.1016/j.injury.2010.03.033, www.injuryjournal.com/article/S0020-1383(10)00233-0/fulltext.

80. **Boukef** et al., *Melatonin, Vitamins and Minerals Supplements for the Treatment of Covid-19 and Covid-like Illness: Results of a Prospective, Randomised, Double-blinded Multicentre Study*, NCT05670444, clinicaltrials.gov/study/NCT05670444.

81. **Piovezan** et al., *Adjuvant Therapeutic Effects of Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19*, NCT04470297, clinicaltrials.gov/study/NCT04470297.

82. **Rodríguez-Rubio** et al., *A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial*, Trials, doi:10.1186/s13063-020-04632-4.

83. **Alizadeh** et al., *High dose melatonin as an adjuvant therapy in intubated patients with COVID-19: A randomized clinical trial*, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.04.012.

84. **Sánchez-González**, *What if melatonin could help COVID-19 severe patients?*, jcsm.aasm.org/doi/10.5664/jcsm.9554.

85. **Treanor** et al., *Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial*, JAMA, 2000, 283:8, 1016-1024, doi:10.1001/jama.283.8.1016.

86. **McLean** et al., *Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial*, Open Forum Infect. Dis. September 2015, 2:3, doi:10.1093/ofid/ofv100.

87. **Ikematsu** et al., *Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts*, New England Journal of Medicine, doi:10.1056/NEJMoa1915341.

88. **Hayden** et al., *Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents*, New England Journal of Medicine, doi:10.1056/NEJMoa1716197.

89. **Kumar** et al., *Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial*, The Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00469-2.

90. **López-Medina** et al., *Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial*, JAMA, doi:10.1001/jama.2021.3071.

91. **Korves** et al., *SARS-CoV-2 Genetic Variants and Patient Factors Associated with Hospitalization Risk*, medRxiv, doi:10.1101/2024.03.08.24303818.

92. **Faria** et al., *Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil*, Science, doi:10.1126/science.abh2644.

93. **Nonaka** et al., *SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and middle-aged patients admitted to the intensive care units of a single hospital in Salvador, Northeast Brazil, February 2021*, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.08.003.

94. **Karita** et al., *Trajectory of viral load in a prospective population-based cohort with incident SARS-CoV-2 G614 infection*, medRxiv, doi:10.1101/2021.08.27.21262754.

95. **Zavascki** et al., *Advanced ventilatory support and mortality in hospitalized patients with COVID-19 caused by Gamma (P.1) variant of concern compared to other lineages: cohort study at a reference center in Brazil*, Research Square, doi:10.21203/rs.3.rs-910467/v1.

96. **Willett** et al., *The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism*, medRxiv, doi:10.1101/2022.01.03.21268111.

97. **Peacock** et al., *The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry*, bioRxiv, doi:10.1101/2021.12.31.474653.

98. **Williams**, T., *Not All Ivermectin Is Created Equal: Comparing The Quality of 11 Different Ivermectin Sources*, Do Your Own Research, doyourownresearch.substack.com/p/not-all-ivermectin-is-created-equal.

99. **Xu** et al., *A study of impurities in the repurposed COVID-19 drug hydroxychloroquine sulfate by UHPLC-Q/TOF-MS and LC-SPE-NMR*, Rapid Communications in Mass Spectrometry, doi:10.1002/rcm.9358.

100. **Jitobaom** et al., *Favipiravir and Ivermectin Showed in Vitro Synergistic Antiviral Activity against SARS-CoV-2*, Research Square, doi:10.21203/rs.3.rs-941811/v1.

101. **Jitobaom (B)** et al., *Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations*, BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00580-8.

102. **Jeffreys** et al., *Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2*, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2022.106542.

103. **Ostrov** et al., *Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells*, Pathogens, doi:10.3390/pathogens10111514.

104. **Alsaidi** et al., *Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral Model*, Marine Drugs, doi:10.3390/md19080418.

105. **Andreani** et al., *In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect*, Microbial Pathogenesis, doi:10.1016/j.micpath.2020.104228.

106. **De Forni** et al., *Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients*, PLoS ONE, doi:10.1371/journal.pone.0276751.

107. **Wan** et al., *Synergistic inhibition effects of andrographolide and baicalin on coronavirus mechanisms by downregulation of ACE2 protein level*, Scientific Reports, doi:10.1038/s41598-024-54722-5.

108. **Said** et al., *The effect of Nigella sativa and vitamin D3 supplementation on the clinical outcome in COVID-19 patients: A randomized controlled clinical trial*, Frontiers in Pharmacology, doi:10.3389/fphar.2022.1011522.

109. **Fiaschi** et al., *In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants*, Viruses, doi:10.3390/v16020168.

110. **Xing** et al., *Published anti-SARS-CoV-2 in vitro hits share common mechanisms of action that synergize with antivirals*, Briefings in Bioinformatics, doi:10.1093/bib/bbab249.

111. **Chen** et al., *Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir*, ACS Pharmacology & Translational Science, doi:10.1021/acsptsci.1c00022.

112. **Hempel** et al., *Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties*, Chemical Science, doi:10.1039/D1SC01494C.

113. **Schultz** et al., *Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2*, Nature, doi:10.1038/s41586-022-04482-x.

114. **Ohashi** et al., *Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment*, iScience, doi:10.1016/j.isci.2021.102367.

115. **Al Krad** et al., *The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication*, bioRxiv, doi:10.1101/2025.03.09.642200.

116. **Thairu** et al., *A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality*, Journal of Pharmaceutical Research International, doi:10.9734/jpri/2022/v34i44A36328.

117. **Singh** et al., *The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis*, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkae045.

118. **Meneguesso**, A., *Médica defende tratamento precoce da Covid-19*, www.youtube.com/watch?v=X5FCrIm_19U.

119. **Boulware**, D., *Comments regarding paper rejection*, twitter.com/boulware_dr/status/1311331372884205570.

120. **Meeus**, G., *Online Comment*, twitter.com/gertmeeus_MD/status/1386636373889781761.

121. **twitter.com**, twitter.com/KashPrime/status/1768487878454124914.

122. **Rothstein**, H., *Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments*, www.wiley.com/en-ae/Publication+Bias+in+Meta+Analysis:+Prevention,+Assessment+and+Adjustments-p-9780470870143.

123. **Stanley** et al., *Meta-regression approximations to reduce publication selection bias*, Research Synthesis Methods, doi:10.1002/jrsm.1095.

124. **Rücker** et al., *Arcsine test for publication bias in meta-analyses with binary outcomes*, Statistics in Medicine, doi:10.1002/sim.2971.

125. **Peters**, J., *Comparison of Two Methods to Detect Publication Bias in Meta-analysis*, JAMA, doi:10.1001/jama.295.6.676.

126. **Moreno** et al., *Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study*, BMC Medical Research Methodology, doi:10.1186/1471-2288-9-2.

127. **Macaskill** et al., *A comparison of methods to detect publication bias in meta-analysis*, Statistics in Medicine, doi:10.1002/sim.698.

128. **Egger** et al., *Bias in meta-analysis detected by a simple, graphical test*, BMJ, doi:10.1136/bmj.315.7109.629.

129. **Harbord** et al., *A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints*, Statistics in Medicine, doi:10.1002/sim.2380.

130. **Sanduzzi Zamparelli** et al., *Immune-Boosting and Antiviral Effects of Antioxidants in COVID-19 Pneumonia: A Therapeutic Perspective*, Life, doi:10.3390/life15010113.

131. **Zhao** et al., *Melatonin Potentially Acts as a Widely-Acting Protective Tool in COVID-19*, Medicine Research, doi:10.21127/yaoyimr20240006.

132. **Yehia** et al., *Melatonin: a ferroptosis inhibitor with potential therapeutic efficacy for the post-COVID-19 trajectory of accelerated brain aging and neurodegeneration*, Molecular Neurodegeneration, doi:10.1186/s13024-024-00728-6.

133. **Chacin-Bonilla** et al., *Melatonin and viral infections: A review focusing on therapeutic effects and SARS-CoV-2*, Melatonin Research, doi:10.32794/mr112500168.

134. **Lempesis** et al., *A mid-pandemic night's dream: Melatonin, from harbinger of anti-inflammation to mitochondrial savior in acute and long COVID-19 (Review)*, International Journal of Molecular Medicine, doi:10.3892/ijmm.2024.5352.

135. **Alomari** et al., *Assessing the antiviral potential of melatonin: A comprehensive systematic review*, Reviews in Medical Virology, doi:10.1002/rmv.2499.

136. **Donzelli**, A., *Neglected Effective Early Therapies against COVID-19: Focus on Functional Foods and Related Active Substances. A Review*, MDPI AG, doi:10.20944/preprints202312.1178.v1.

137. **Langen**, M., *Melatonin - the Hormone of Both Sun and Darkness - Protects Your Health and Can Save Your Life*, Rounding The Earth, roundingtheearth.substack.com/p/melatonin-the-hormone-of-both-sun.

138. **Hosseinzadeh** et al., *Melatonin effect on platelets and coagulation: Implications for a prophylactic indication in COVID-19*, Life Sciences, doi:10.1016/j.lfs.2022.120866.

139. **Tan** et al., *Mechanisms and clinical evidence to support melatonin's use in severe COVID-19 patients to lower mortality*, Life Sciences, doi:10.1016/j.lfs.2022.120368.

140. **Behl (B)** et al., *CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target*, Science of The Total Environment, doi:10.1016/j.scitotenv.2021.152072.

141. **Castle** et al., *Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation*, Journal of Inflammation Research, doi:10.2147/JIR.S323356.

142. **Ramos** et al., *The Coronavirus Disease 2019 (COVID-19): Key Emphasis on Melatonin Safety and Therapeutic Efficacy*, Antioxidants, doi:10.3390/antiox10071152.

143. **Camp** et al., *Melatonin interferes with COVID-19 at several distinct ROS-related steps*, Journal of Inorganic Biochemistry, doi:10.1016/j.jinorgbio.2021.111546.

144. **Cross** et al., *Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy*, Endocrine Practice, doi:10.1016/j.eprac.2021.06.001.

145. **DiNicolantonio** et al., *Melatonin may decrease risk for and aid treatment of COVID-19 and other RNA viral infections*, Open Heart, doi:10.1136/openhrt-2020-001568.

146. **Reiter (C)** et al., *Therapeutic Algorithm for Use of Melatonin in Patients With COVID-19*, Frontiers in Medicine, doi:10.3389/fmed.2020.00226.

147. **Charaa** et al., *Prophylactic Treatment Protocol against the Severity of COVID-19 Using Melatonin*, SSRN, doi:10.2139/ssrn.3601861.

148. **Shneider** et al., *Can melatonin reduce the severity of COVID-19 pandemic?*, International Reviews of Immunology, doi:10.1080/08830185.2020.1756284.

149. **Alizadeh (B)** et al., *A Pilot Study on Controlling Coronavirus Disease 2019 (COVID-19) Inflammation Using Melatonin Supplement*, Iranian Journal of Allergy, Asthma and Immunology, ijaai.tums.ac.ir/index.php/ijaai/article/view/3086.

150. **Lissoni** et al., *COVID-19 Disease as an Acute Angiotensin 1-7 Deficiency: A Preliminary Phase 2 Study with Angiotensin 1-7 in Association with Melatonin and Cannabidiol in Symptomatic COVID19 -Infected Subjects*, Journal of Infectiology, doi:10.29245/2689-9981/2018/2.1162.

151. **Tian** et al., *Association between ramelteon and 30-day mortality in ICU patients with COVID-19: A retrospective analysis of the MIMIC-IV database*, British Journal of Clinical Pharmacology, doi:10.1002/bcp.70099.

152. **Ameri** et al., *Efficacy and safety of oral melatonin in patients with severe COVID-19: a randomized controlled trial*, Inflammopharmacology, doi:10.1007/s10787-022-01096-7.

153. **Fogleman** et al., *A Pilot of a Randomized Control Trial of Melatonin and Vitamin C for Mild-to-Moderate COVID-19*, The Journal of the American Board of Family Medicine, doi:10.3122/jabfm.2022.04.210529.

154. **Fernandez-Tresguerres** et al., *Safety and Efficacy of Drugs Given Off-label for COVID-19*, NCT05596617, clinicaltrials.gov/study/NCT05596617.

155. **Karimpour-razkenari** et al., *Melatonin as adjunctive therapy in patients admitted to the Covid-19*, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103492.

156. **Sánchez-Rico** et al., *Melatonin does not reduce mortality in adult hospitalized patients with COVID-19: a multicenter retrospective observational study*, Journal of Travel Medicine, doi:10.1093/jtm/taab195.

157. **Bologna** et al., *Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for COVID-19: A Retrospective Observational Study*, Journal of Clinical Medicine, doi:10.3390/jcm10245857.

158. **Hasan** et al., *The Effect of Melatonin on Thrombosis, Sepsis and Mortality Rate in COVID-19 Patients*, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.10.012.

159. **Mousavi** et al., *Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial*, Journal of Medical Virology, doi:10.1002/jmv.27312.

160. **Farnoosh** et al., *Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial*, Archives of Medical Research, doi:10.1016/j.arcmed.2021.06.006.

161. **Hosseini** et al., *Evaluation of Th1 and Th2 mediated cellular and humoral immunity in patients with COVID-19 following the use of melatonin as an adjunctive treatment*, European Journal of Pharmacology, doi:10.1016/j.ejphar.2021.174193.

162. **Darban** et al., *Efficacy of High Dose Vitamin C, Melatonin and Zinc in Iranian Patients with Acute Respiratory Syndrome due to Coronavirus Infection: A Pilot Randomized Trial*, Journal of Cellular & Molecular Anesthesia, doi:10.22037/jcma.v6i2.32182.

163. **Ramlall** et al., *Melatonin is significantly associated with survival of intubated COVID-19 patients*, medRxiv, doi:10.1101/2020.10.15.20213546.

164. **Castillo** et al., *Melatonin as adjuvant treatment for coronavirus disease 2019 pneumonia patients requiring hospitalization (MAC-19 PRO): a case series*, Melatonin Research, doi:10.32794/mr11250063.

165. **García-García** et al., *Melatonin in the Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers (MeCOVID): A Randomised Clinical Trial*, Journal of Clinical Medicine, doi:10.3390/jcm11041139.

166. **Zhou** et al., *A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19*, PLOS Biology, doi:10.1371/journal.pbio.3000970.

167. **Jehi** et al., *Individualizing Risk Prediction for Positive Coronavirus Disease 2019 Testing*, Chest, doi:10.1016/j.chest.2020.05.580.

168. **Ma** et al., *Advances in acute respiratory distress syndrome: focusing on heterogeneity, pathophysiology, and therapeutic strategies*, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-025-02127-9.

169. **Qudus** et al., *SARS-CoV-2-ORF-3a Mediates Apoptosis Through Mitochondrial Dysfunction Modulated by the K+ Ion Channel*, International Journal of Molecular Sciences, doi:10.3390/ijms26041575.

170. **Girgis** et al., *Indole-based compounds as potential drug candidates for SARS-CoV-2*, MDPI AG, doi:10.20944/preprints202308.0746.v1.

171. **Lei** et al., *Small molecules in the treatment of COVID-19*, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-022-01249-8.

172. **Loucera** et al., *Drug repurposing for COVID-19 using machine learning and mechanistic models of signal transduction circuits related to SARS-CoV-2 infection*, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00417-y.

173. **Ma (B)** et al., *Integration of human organoids single-cell transcriptomic profiles and human genetics repurposes critical cell type-specific drug targets for severe COVID-19*, Cell Proliferation, doi:10.1111/cpr.13558.

174. **Zhou (B)** et al., *Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2*, Cell Discovery, doi:10.1038/s41421-020-0153-3.

175. **Gysi** et al., *Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19*, arXiv, doi:10.48550/arXiv.2004.07229.

176. **Marwick** et al., *Application of a High-Content Screening Assay Utilizing Primary Human Lung Fibroblasts to Identify Antifibrotic Drugs for Rapid Repurposing in COVID-19 Patients*, SLAS Discovery, doi:10.1177/24725552211019405.

177. **Huang** et al., *Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS)*, Respiratory Research, doi:10.1186/s12931-024-02678-5.

178. **Senger** et al., *COVID-19: molecular targets, drug repurposing and new avenues for drug discovery*, Memórias do Instituto Oswaldo Cruz, doi:10.1590/0074-02760200254.

179. **Khan** et al., *Possible therapeutic targets for SARS-CoV-2 infection and COVID-19*, Journal of Allergy & Infectious Diseases, doi:10.46439/allergy.2.028.

180. **Kushwaha** et al., *A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19*, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719.

181. **Akter** et al., *Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations*, Heliyon, doi:10.1016/j.heliyon.2023.e17478.

182. **Lundstrom** et al., *COVID-19 signalome: Potential therapeutic interventions*, Cellular Signalling, doi:10.1016/j.cellsig.2022.110559.

183. **Oliver** et al., *Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus*, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845.

184. **Wang (D)** et al., *Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations*, Circulation Research, doi:10.1161/circresaha.122.321879.

185. **Kumar (B)** et al., *COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery*, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019.

186. **Raghav** et al., *Potential treatments of COVID-19: Drug repurposing and therapeutic interventions*, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004.

187. **Supianto** et al., *Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature*, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015.

188. **Zeng** et al., *Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning*, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316.

189. **Sperry** et al., *Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients*, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050.

190. ***c19early.org (D)***, c19early.org/timeline.html.

191. **Mateja** et al., *The choice of viral load endpoint in early phase trials of COVID-19 treatments aiming to reduce 28-day hospitalization and/or death*, The Journal of Infectious Diseases, doi:10.1093/infdis/jiaf282.

192. ***Zhang (B)*** et al., *What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes*, JAMA, 80:19, 1690, doi:10.1001/jama.280.19.1690.

193. **Altman**, D., *How to obtain the P value from a confidence interval*, BMJ, doi:10.1136/bmj.d2304.

194. ***Altman (B)*** et al., *How to obtain the confidence interval from a P value*, BMJ, doi:10.1136/bmj.d2090.

195. **Sweeting** et al., *What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data*, Statistics in Medicine, doi:10.1002/sim.1761.

196. **Deng**, H., *PyMeta, Python module for meta-analysis*, www.pymeta.com/.